Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
59
RPRX Quote, Financials, Valuation and Earnings
Last price:
$47.43
Seasonality move
:
-6.97%
Day range:
$46.44 - $47.66
52-week range:
$29.66 - $47.66
Dividend yield:
1.89%
P/E ratio:
26.67x
P/S ratio:
10.62x
P/B ratio:
3.14x
Volume:
3.7M
Avg. volume:
3.9M
1-year change:
40.22%
Market cap:
$20.3B
Revenue:
$2.4B
EPS (TTM):
$1.78
Analysts' Opinion
-
Consensus RatingRoyalty Pharma Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $51.56, Royalty Pharma Plc has an estimated upside of 8.58% from its current price of $47.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $46.00 representing 3.12% downside risk from its current price of $47.48.
Fair Value
-
According to the consensus of 8 analysts, Royalty Pharma Plc has 8.58% upside to fair value with a price target of $51.56 per share.
RPRX vs. S&P 500
-
Over the past 5 trading days, Royalty Pharma Plc has overperformed the S&P 500 by 6% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Royalty Pharma Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Royalty Pharma Plc has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Royalty Pharma Plc reported revenues of $622M.
Earnings Growth
-
Royalty Pharma Plc has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Royalty Pharma Plc reported earnings per share of $0.50.
Enterprise value:
31.9B
EV / Invested capital:
1.71x
Price / LTM sales:
10.62x
EV / EBIT:
20.47x
EV / Revenue:
13.42x
PEG ratio (5yr expected):
0.34x
EV / Free cash flow:
35.56x
Price / Operating cash flow:
28.16x
Enterprise value / EBITDA:
20.43x
Gross Profit (TTM):
$1.2B
Return On Assets:
7.11%
Net Income Margin (TTM):
55.68%
Return On Equity:
13.52%
Return On Invested Capital:
7.35%
Operating Margin:
62.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $2.4B | $2.3B | $2.4B | $594M | $622M | |
| Gross Profit | -- | -- | $1.2B | -- | $620.8M | |
| Operating Income | $1.5B | $1.3B | $1.6B | $361M | $388M | |
| EBITDA | $1.5B | $1.3B | $1.6B | $361M | $389.2M | |
| Diluted EPS | $2.54 | $1.92 | $1.78 | $0.47 | $0.50 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.9B | $2.6B | $1.3B | $1.8B | $1.5B | |
| Total Assets | $17.5B | $16.8B | $16.4B | $18.2B | $19.6B | |
| Current Liabilities | $171.3M | $1.2B | $161.4M | $1.3B | $636.2M | |
| Total Liabilities | $7.3B | $7.3B | $6.3B | $7.9B | $9.9B | |
| Total Equity | $10.2B | $9.5B | $10.1B | $10.3B | $9.7B | |
| Total Debt | $7.1B | $7.1B | $6.1B | $7.6B | $9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3B | $2.8B | $2.6B | $745.8M | $832.1M | |
| Cash From Investing | -$2.1B | -$2.7B | -$1.7B | -$507.6M | -$852.8M | |
| Cash From Financing | -$2.2B | $356M | -$1.2B | -$259.2M | -$299.6M | |
| Free Cash Flow | $916.2M | $268.9M | $897.2M | $249.4M | $98.5M | |
RPRX
Sector
Market Cap
$20.3B
$25.3M
Price % of 52-Week High
99.63%
49.41%
Dividend Yield
1.89%
0%
Shareholder Yield
8.05%
-1.6%
1-Year Price Total Return
40.23%
-17.71%
Beta (5-Year)
0.403
0.490
Dividend yield:
1.89%
Annualized payout:
$0.88
Payout ratio:
44.07%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$45.96
200-day SMA
Buy
Level
$37.81
Bollinger Bands (100)
Buy
Level
37.21 - 42.95
Chaikin Money Flow
Buy
Level
13.6M
20-day SMA
Buy
Level
$45.07
Relative Strength Index (RSI14)
Buy
Level
81.88
ADX Line
Buy
Level
23.59
Williams %R
Sell
Level
-3.3948
50-day SMA
Buy
Level
$41.98
MACD (12, 26)
Buy
Level
12.81
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
8.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6095)
Sell
CA Score
(Annual)
Level (-0.712)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.9711)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, RPRX has received 6 Buy ratings 2 Hold ratings, and 0 Sell ratings. The RPRX average analyst price target in the past 3 months is $51.56.
-
Where Will Royalty Pharma Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Royalty Pharma Plc share price will rise to $51.56 per share over the next 12 months.
-
What Do Analysts Say About Royalty Pharma Plc?
Analysts are divided on their view about Royalty Pharma Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Royalty Pharma Plc is a Sell and believe this share price will drop from its current level to $46.00.
-
What Is Royalty Pharma Plc's Price Target?
The price target for Royalty Pharma Plc over the next 1-year time period is forecast to be $51.56 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Royalty Pharma Plc is a Buy. 6 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RPRX?
You can purchase shares of Royalty Pharma Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Royalty Pharma Plc shares.
-
What Is The Royalty Pharma Plc Share Price Today?
Royalty Pharma Plc was last trading at $47.43 per share. This represents the most recent stock quote for Royalty Pharma Plc. Yesterday, Royalty Pharma Plc closed at $47.48 per share.
-
How To Buy Royalty Pharma Plc Stock Online?
In order to purchase Royalty Pharma Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RPRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RPRX
Sector
P/E ratio
26.67x
22.85x
PEG ratio
0.34x
-0.01x
P/B ratio
3.14x
1.78x
Price / LTM sales
10.62x
1.52x
Growth Metrics
RPRX
Sector
Revenue growth
4.71%
3.33%
Earnings growth
6.83%
11.64%
Revenue (5-year growth)
2.3%
6.41%
Earnings forecast
$1.33
-$0.20
Profitability
RPRX
Sector
Profitability FY 2025
$2.4B
$2.3M
Return on invested capital
7.35%
-33.31%
Return on assets
7.11%
-29.79%
Return on equity
13.52%
-38.98%
Earnings Date
Last Earnings Date
Feb
11
Next Earnings Date
May
7
Estimated Next Earnings Date
May
13
Balance Sheet
RPRX
Sector
Total cash
$637.5M
$24.1M
Short term investments
$842M
$23.8M
Total assets
$19.6B
$70.1M
Long term debt
$9B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
